secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001193125-25-105825
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial
--------------------------------------------------------------------------------

- Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
- Data presented at ELITE PED-GI Congress; stool volume/frequency reduced and urine output increased, indicating improved oral absorption.
- No approved drugs exist for MVID; crofelemer may qualify for EMA PRIME and FDA Breakthrough Therapy programs.
- Company supports three investigator-initiated trials and two placebo-controlled Phase 2 studies for MVID/SBS-IF globally.
- Additional POC results from IITs expected throughout 2025; early patient access possible in certain EU countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/0001193125-25-105825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525105825/d935544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-105825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer